The group's principal activities are to develop a series of catalytic antioxidant molecules which protect against the damaging effects of reactive oxygen derived molecules. The group's target application will be the use of catalytic antioxidants to limit the side effects from damage caused by free radicals occurring in cancer radiation therapy. Free radicals, such as superoxide and peroxynitrite, cause damage in a broad group of diseases and conditions. The group was also developing adult liver stem cell therapy for the treatment of liver failure, which was sold in Oct 2002. On Oct 31, 2002, the group sold substantially all the assets of its wholly owned subsidiary, incara cell technologies, inc.
